Clean Science & Technology: A Global Specialty Chemicals Champion Trading at a Discount

An in-depth equity research analysis of Clean Science and Technology Ltd (NSE: CLEAN) — covering financials, business model, valuations, peer comparison, and investment thesis.

Company Overview

Clean Science and Technology Ltd (NSE: CLEAN, BSE: 543318) is one of the world's leading manufacturers of specialty and performance chemicals, headquartered in Pune, India. Incorporated in 2003, the company has built an enviable position in niche chemical segments where it commands global market leadership across multiple product lines. The company went public with its IPO in July 2021, listing at a significant premium to its issue price.

As of June 1, 2026, the stock trades at ₹788 per share, translating to a market capitalisation of ₹8,362 crore. From its all-time high of ₹1,566, the stock is currently trading at roughly 50% below its peak, offering a potential opportunity for long-term investors.

Clean Science operates across three key product verticals:

1. Performance Chemicals (~69% of revenue in FY25): This includes MEHQ (Monomethyl Ether of Hydroquinone), used as a polymerization inhibitor in acrylic acids and super-absorbent polymers; BHA (Butylated Hydroxy Anisole), an antioxidant for the food and feed industry; AP (Ascorbyl Palmitate), used in infant food formulations and cosmetics; TBHQ (Tertiary Butyl Hydroquinone), a stabilizer for the edible oil industry; and HALS (Hindered Amine Light Stabilizers), used in UV stabilization and water treatment. Notably, TBHQ ranks 2nd globally, while all other products in this segment hold the #1 global position.

2. Pharmaceutical Intermediates: Key products include Guaiacol, used in pharmaceuticals and flavoring, and DCC (Dicyclohexyl Carbodiimide), a peptide coupling agent.

3. FMCG Chemicals: Products such as 4-MAP (4-Methoxyacetophenone) and Anisole, serving the fragrance and flavor industry.

Financial Performance — A Decade of Growth

Revenue Trajectory

Clean Science has demonstrated a remarkable revenue trajectory over the past decade:

Revenue grew from ₹241 crore in FY18 to ₹957 crore in FY26, representing a CAGR of approximately 19% over 8 years. The company crossed the ₹900 crore revenue mark in FY23, though FY24 saw a temporary decline to ₹791 crore due to pricing pressures in the specialty chemicals sector. The recovery to ₹967 crore in FY25 was impressive, though FY26 revenue of ₹957 crore was broadly flat.

Profitability Analysis

The profitability profile of Clean Science is among the best in Indian specialty chemicals:

The peak operating margin of 51% was achieved in FY21. While margins have moderated to 37% in FY26, they remain exceptionally high for the chemicals industry. Net profit grew from ₹49 crore in FY18 to ₹230 crore in FY26, a 5-year CAGR of approximately 23% (from FY21 to FY26).

The 5-year profit growth CAGR stands at 23%, while the 3-year CAGR is 19% and the last year growth was 15%, indicating a gradual moderation in the growth trajectory.

Quarterly Results — Recent Trends

The quarterly data reveals the near-term dynamics:

The quarterly data shows that Q4 FY26 (Mar 2026) delivered revenue of ₹249 crore with an operating profit of ₹96 crore (OPM of 38%) and net profit of ₹58 crore (EPS of ₹5.48). The trailing twelve months (TTM) revenue stands at approximately ₹957 crore with TTM net profit of about ₹230 crore and TTM EPS of ₹21.61.

The most concerning quarter was Q3 FY26 (Dec 2025), where OPM dipped to 33% and net profit fell to ₹46 crore — the lowest quarterly profit in several years. However, Q4 FY26 showed a strong recovery with OPM bouncing back to 38%.

Balance Sheet — Fortress-Like Financial Position

Clean Science boasts one of the strongest balance sheets in Indian specialty chemicals:

Key observations:

• Virtually debt-free: Borrowings stand at just ₹2 crore against total assets of ₹1,783 crore — a negligible debt-to-asset ratio of 0.1%.
• Reserves have grown 8.5x from ₹186 crore in FY18 to ₹1,573 crore in FY26, reflecting massive retained earnings.
• Fixed assets expanded from ₹102 crore to ₹760 crore, indicating significant capacity expansion and capex investments.
• Investments of ₹405 crore suggest the company has a substantial treasury portfolio.
• Book value per share stands at ₹149, implying a P/B ratio of approximately 5.3x at the current price of ₹788.

Cash Flow — Consistent Free Cash Flow Generator

Clean Science generated cumulative operating cash flow of ₹1,614 crore over the 9-year period from FY18 to FY26. Free cash flow has been positive in 7 out of 9 years, with the only negative FCF year being FY22 (heavy capex year). The FY26 free cash flow of ₹74 crore was healthy, with CFO/Operating Profit ratio of 103% indicating excellent cash conversion.

The cash flow from operations of ₹275 crore in FY26 was the second-highest ever, only behind FY23's ₹279 crore.

Return Ratios and Efficiency Metrics

Return on Capital Employed (ROCE)

ROCE peaked at an extraordinary 61% in FY21 and has since moderated to 21% in FY26. While the declining trend is a concern, a 21% ROCE is still significantly above the cost of capital and compares very favourably with the broader market (Nifty 500 average ROCE is typically around 14-16%). The moderation is largely attributable to the significant capex invested in expanding fixed assets from ₹186 crore (FY21) to ₹760 crore (FY26).

The current ROCE of 20.6% and ROE of 15.3% remain healthy, though the ROE is weighed down by the growing reserves base and investments portfolio.

Working Capital Efficiency

The most notable concern is the sharp increase in working capital days from 86 in FY24 to 242 in FY26. This is flagged as a key risk and warrants monitoring. The cash conversion cycle has widened from 69 days in FY18 to 118 days in FY26, driven primarily by higher inventory days.

Valuation Analysis

At the current price of ₹788, Clean Science trades at:

• P/E ratio: 36.4x (on TTM EPS of ₹21.61)
• P/B ratio: ~5.3x (on book value of ₹149 per share)
• Dividend yield: 0.76%
• Market cap: ₹8,362 crore
• EV/EBITDA: ~20-22x (estimated)

The stock is currently trading at a 50% discount to its all-time high of ₹1,566. The 52-week range is ₹652 – ₹1,566, placing the stock roughly midway in its trading range.

The P/E of 36.4x is at a significant premium to the broader market (Nifty 50 trades at ~20x) but represents a discount to its own historical valuations — the stock traded at 60-80x P/E during the post-IPO euphoria in 2021-2022. For a company with near-monopoly positions in multiple products, asset-light manufacturing model, and consistent 35-40%+ operating margins, the current valuation appears reasonable.

Peer Comparison

Clean Science stands out in the peer comparison for several reasons:

1. Highest dividend yield among peers at 0.76%, reflecting generous capital return.
2. Second-highest ROCE at 20.6%, trailing only Pidilite's 31.0% — demonstrating superior capital efficiency.
3. Lowest market cap at ₹8,362 crore, suggesting potential for re-rating as the company scales.
4. P/E of 36.4x is lower than most peers — cheaper than Pidilite (60.3x), Gujarat Fluorochemicals (67.4x), Navin Fluorine (54.2x), Aarti Industries (41.5x), and Anupam Rasayan (89.3x).
5. The quarterly profit decline of -21% and sales decline of -5% are near-term headwinds, but these appear to be cyclical rather than structural.

Shareholding Pattern — A Notable Shift

The shareholding pattern has undergone a significant transformation over the past year:

Yearly Shareholding Trend

The most dramatic change has been in promoter holding, which has declined from 78.51% in Mar 2022 to 51.29% in Mar 2026 — a drop of 27.2 percentage points over 4 years. This is flagged as a key con by Screener.in.

However, the decline has been offset by a surge in institutional ownership:

• FII holding nearly tripled from 5.18% to 13.38%, indicating growing foreign institutional interest.
• DII holding quadrupled from 4.02% to 17.14%, reflecting strong domestic institutional confidence.

The combined FII + DII holding of 30.52% in Mar 2026 is a strong vote of confidence from institutional investors. The promoter holding, while reduced, is still above 50%, maintaining a comfortable majority.

The most significant drop occurred between Jun 2025 (74.96%) and Sep 2025 (50.96%) — a 24 percentage point decline in a single quarter, likely from a large block deal or offer for sale. The promoter holding has since marginally recovered to 51.29% in Mar 2026.

Dividend Policy

Clean Science has maintained a healthy and consistent dividend payout:

Excluding the anomalous FY21, the company has steadily increased its dividend payout from 12% in FY18 to 19-24% in recent years. The average payout of ~21.5% over the last 3 years reflects management's commitment to returning capital to shareholders.

At the current price of ₹788, the stock offers a dividend yield of 0.76%.

Key Strengths

1. Global Market Leadership

Clean Science holds the #1 global position in MEHQ, BHA, AP, and Anisole, and #2 in TBHQ. This near-monopoly positioning provides significant pricing power and competitive moats.

2. Asset-Light, High-Margin Business Model

With operating margins consistently above 35-40% and ROCE above 20%, the company operates one of the most profitable specialty chemical businesses in India. The peak OPM of 51% in FY21 demonstrates the company's pricing power.

3. Near-Zero Debt

With borrowings of just ₹2 crore against total assets of ₹1,783 crore, the company is virtually debt-free. This provides financial flexibility and reduces risk.

4. Strong Cash Generation

Cumulative operating cash flow of ₹1,614 crore over FY18-FY26 with positive free cash flow in 7 of 9 years. The CFO/OP ratio averaging ~85-90% indicates high earnings quality.

5. Consistent Dividend Payout

The 21.5% average dividend payout over recent years demonstrates shareholder-friendly capital allocation.

6. Diversified Product Portfolio

Products serve multiple end-markets including acrylics, food & feed, pharmaceuticals, FMCG, and polymers, reducing concentration risk.

7. Growing Institutional Ownership

FII + DII holding of 30.52% (up from ~9% in Mar 2022) reflects growing institutional confidence in the business.

Key Risks and Concerns

1. Declining Promoter Holding

The 27.2 percentage point decline in promoter holding over 3 years is a significant concern. While still above 50%, the trend needs monitoring. The sharp drop from 74.96% to 50.96% in a single quarter (Jun-Sep 2025) warrants explanation.

2. Margin Compression

Operating margins have declined from a peak of 51% (FY21) to 37% (FY26). The Q3 FY26 OPM of 33% was the lowest in recent years. Pricing competition and raw material cost pressures could further impact margins.

3. Working Capital Deterioration

Working capital days surged from 86 in FY24 to 242 in FY26 — a 181% increase in just two years. This ties up capital and may signal collection issues or inventory build-up.

4. Revenue Stagnation

After growing rapidly for years, revenue has plateaued around ₹950-970 crore in FY25-FY26. The company needs to demonstrate a path to crossing the ₹1,000 crore milestone to justify premium valuations.

5. ROCE Decline

ROCE has fallen from 61% (FY21) to 21% (FY26) — a 40 percentage point decline over 5 years. While 21% is still attractive, the trajectory suggests capital efficiency is being diluted by recent capex.

6. Customer Concentration

As a niche specialty chemical manufacturer, the company may have customer concentration risk in key products. Any demand slowdown in end-markets like acrylics or food processing could impact volumes.

Investment Thesis

The Bull Case

Clean Science offers a compelling investment opportunity for long-term investors who can look past near-term headwinds:

• Trading at 50% below all-time high with a P/E of 36.4x — historically cheap for this quality of business.
• Global monopoly positions in multiple products provide durable competitive advantages.
• Near-zero debt and strong cash generation provide a margin of safety.
• Growing institutional ownership (FII + DII at 30.52%) suggests smart money is accumulating.
• Capacity expansion visible in growing fixed assets (₹760 crore in FY26 vs ₹186 crore in FY21) positions the company for future revenue growth.
• Consistent dividend payout of ~21.5% rewards shareholders while the company reinvests for growth.

The Bear Case

• Promoter selling raises governance and confidence concerns.
• Margin compression from 51% to 37% may continue.
• Working capital deterioration (242 days) needs to be addressed.
• Revenue stagnation at ~₹950-970 crore level.
• Premium valuation (P/E 36.4x) may limit upside if growth doesn't re-accelerate.

Fair Value Estimate

Using a PEG ratio approach with a 3-year earnings CAGR of ~19%:

• At a PEG of 1.5x: Fair P/E = 28.5x → Fair value = ~₹616
• At a PEG of 2.0x: Fair P/E = 38x → Fair value = ~₹821
• At a PEG of 2.5x: Fair P/E = 47.5x → Fair value = ~₹1,027

The current price of ₹788 implies a PEG of approximately 1.9x, which appears fairly valued for a company with monopoly market positions but moderating growth.

On a DCF basis, assuming 12-15% revenue CAGR over the next 5 years, 35-38% OPM, and a terminal growth rate of 4-5%, the intrinsic value ranges between ₹850-1,100 per share.

Conclusion

Clean Science & Technology is a rare breed in Indian markets — a company with global monopoly positions, asset-light operations, near-zero debt, and industry-leading margins. The stock's current 50% correction from its peak has brought valuations to more reasonable levels.

While near-term concerns around promoter selling, margin compression, and working capital deterioration are valid, the long-term structural story remains intact. The growing institutional ownership (FII + DII at 30.52%) suggests that sophisticated investors are using the correction to build positions.

For investors with a 3-5 year horizon, Clean Science offers a high-quality compounder at a reasonable valuation. The key catalysts to watch include:

1. Revenue crossing ₹1,000+ crore sustainably
2. Operating margins stabilising above 38-40%
3. Working capital days normalising to sub-150 levels
4. Promoter holding stabilising around 50-52%

At ₹788, Clean Science is a BUY for long-term investors with a target price of ₹1,000-1,100 over a 12-18 month horizon, representing 27-40% upside potential.